Literature DB >> 8203549

Recombinant GM-CSF reduces lung injury and mortality during neutropenic Candida sepsis.

A J Lechner1, K E Lamprech, L H Potthoff, T L Tredway, G M Matuschak.   

Abstract

Cyclophosphamide (CY)-induced neutropenia exacerbates septic shock and acute lung injury during Candida albicans (CA) fungemia in conscious rats. We hypothesized that treatment of such animals with recombinant murine granulocyte-macrophage colony-stimulating factor (GM-CSF) improves host defense during disseminated candidiasis by increasing peripheral neutrophils (PMNs) and enhancing endogenous production of antifungal cytokines including tumor necrosis factor-alpha (TNF). Naive (neutrophil-replete) or neutropenic rats were infected with 10(7) yeast-phase CA; subgroups received GM-CSF (25 micrograms/kg sc) or sterile 0.9% NaCl (NS) twice a day beginning 3 days before CA infection. Arterial hemodynamics, formed blood elements, bioactive TNF in serum and bronchoalveolar lavage fluid (BALF), and lung histopathology were monitored for up to 72 h after infection. All naive animals receiving GM-CSF (n = 5) and 78% of naive rats given NS (n = 9) remained normotensive through 72 h with no lung injury, differing principally in baseline PMNs before CA infection (8.8 +/- 1.8 x 10(3)/microliters, mean +/- SE, vs. 3.7 +/- 0.4 x 10(3)/microliters, respectively, P < 0.01). Neutropenic rats given NS (baseline PMN = 41 +/- 10/microliters, n = 7) were sensitized to CA, and 100% died of hypothermic shock with severe respiratory distress within 56 h of infection. Pulmonary periarterial and alveolar hemorrhage were prominent. Although GM-CSF did not increase baseline PMNs in CY animals by the outset of infection (162 +/- 58/microliters, n = 8), 62% of these rats remained normotensive and eupneic through 72 h (P < 0.01), and their lungs showed no perivascular hemorrhage, alveolar disruption, or fungi.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8203549     DOI: 10.1152/ajplung.1994.266.5.L561

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

Review 1.  Nonventilatory treatments for acute lung injury and ARDS.

Authors:  Carolyn S Calfee; Michael A Matthay
Journal:  Chest       Date:  2007-03       Impact factor: 9.410

2.  Novel GM-CSF signals via IFN-γR/IRF-1 and AKT/mTOR license monocytes for suppressor function.

Authors:  Eliana Ribechini; James A Hutchinson; Sabine Hergovits; Marion Heuer; Jörg Lucas; Ulrike Schleicher; Ana-Laura Jordán Garrote; Sarah J Potter; Paloma Riquelme; Heike Brackmann; Nora Müller; Hartmann Raifer; Ingolf Berberich; Magdalena Huber; Andreas Beilhack; Michael Lohoff; Christian Bogdan; Matthias Eyrich; Heike M Hermanns; Edward K Geissler; Manfred B Lutz
Journal:  Blood Adv       Date:  2017-06-07

Review 3.  Hematopoietic growth factors in cancer patients with invasive fungal infections.

Authors:  F Offner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

4.  Immunomodulatory and protective effects of moxifloxacin against Candida albicans-induced bronchopneumonia in mice injected with cyclophosphamide.

Authors:  Itamar Shalit; Limor Horev-Azaria; Ina Fabian; Hannah Blau; Naam Kariv; Itsak Shechtman; Hannah Alteraz; Yehudith Kletter
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

5.  The Pathophysiology and Treatment of Candida Sepsis.

Authors:  Brad Spellberg; John E. Edwards
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

Review 6.  Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; Gloria S Pryhuber; Patricia R Chess; Bruce A Davidson; Paul R Knight; Robert H Notter
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

7.  Is low monocyte HLA-DR expression helpful to predict outcome in severe sepsis?

Authors:  Sara E Perry; Sobhy M Mostafa; Richard Wenstone; Alan Shenkin; Paul J McLaughlin
Journal:  Intensive Care Med       Date:  2003-05-28       Impact factor: 17.440

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.